ATE554109T1 - Adenocarcinomspezifischer antikörper sam-6 und anwendungen dafür - Google Patents

Adenocarcinomspezifischer antikörper sam-6 und anwendungen dafür

Info

Publication number
ATE554109T1
ATE554109T1 AT04797921T AT04797921T ATE554109T1 AT E554109 T1 ATE554109 T1 AT E554109T1 AT 04797921 T AT04797921 T AT 04797921T AT 04797921 T AT04797921 T AT 04797921T AT E554109 T1 ATE554109 T1 AT E554109T1
Authority
AT
Austria
Prior art keywords
applications
specific antibody
antibody sam
sam
adenocarcinoma
Prior art date
Application number
AT04797921T
Other languages
English (en)
Inventor
Heinz Vollmers
Hans-Konrad Mueller-Hermelink
Original Assignee
Patrys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patrys Ltd filed Critical Patrys Ltd
Application granted granted Critical
Publication of ATE554109T1 publication Critical patent/ATE554109T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04797921T 2003-11-14 2004-11-12 Adenocarcinomspezifischer antikörper sam-6 und anwendungen dafür ATE554109T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03026161A EP1531162A1 (de) 2003-11-14 2003-11-14 Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
PCT/EP2004/012970 WO2005047332A1 (en) 2003-11-14 2004-11-12 Adenocarcinoma specific antibody sam-6, and uses thereof

Publications (1)

Publication Number Publication Date
ATE554109T1 true ATE554109T1 (de) 2012-05-15

Family

ID=34429369

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04797921T ATE554109T1 (de) 2003-11-14 2004-11-12 Adenocarcinomspezifischer antikörper sam-6 und anwendungen dafür

Country Status (7)

Country Link
US (2) US8163552B2 (de)
EP (3) EP1531162A1 (de)
JP (1) JP2008507951A (de)
AT (1) ATE554109T1 (de)
AU (1) AU2004289821B2 (de)
CA (1) CA2545454C (de)
WO (1) WO2005047332A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003249533A1 (en) 2002-07-04 2004-01-23 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
DE10353175A1 (de) * 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (de) 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
CA2683287A1 (en) * 2006-11-27 2008-12-18 Patrys Limited Novel glycosylated peptide target in neoplastic cells
WO2009104100A2 (en) * 2008-02-19 2009-08-27 Patrys Limited Antibody combinations, and methods of making and using same
JP2012517216A (ja) * 2009-02-09 2012-08-02 パトリス リミテッド Ｓａｍ−６変異体、標的および使用法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
DE3722647A1 (de) 1987-07-09 1989-01-19 Gerhard Ohlenschlaeger Galenische verwendung eines tripeptids als arzneimittel
DE4107154A1 (de) 1990-10-11 1992-04-16 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen melanom
AU662311B2 (en) 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
GB9105292D0 (en) 1991-03-13 1991-04-24 Sandoz Ltd Improvements in or relating to organic compounds
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5639863A (en) * 1994-06-21 1997-06-17 Dan; Michael D. Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
CA2269204C (en) 1996-10-18 2012-01-24 Genentech, Inc. Anti-erbb2 antibodies
ATE516354T1 (de) * 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
US6185924B1 (en) 1997-10-17 2001-02-13 Hitachi, Ltd. Gas turbine with turbine blade cooling
EP0927757A1 (de) 1997-12-03 1999-07-07 Leadd B.V. Verfahren und Mitteln um Apoptose zu induzieren durch Interferenz mit Bip-ähnliche Proteine
CA2319089A1 (en) * 1998-04-09 1999-10-21 Genset S.A. 5' ests and encoded human proteins
US6846637B1 (en) 1998-06-18 2005-01-25 Imed Ab Fas peptides and antibodies for modulating apoptosis
ATE217889T1 (de) * 1998-08-28 2002-06-15 Genentech Inc Humane antikörper gegen faktor ix/ixa
GB9822115D0 (en) 1998-10-09 1998-12-02 King S College London Treatment of inflammatory disease
EP1141019B1 (de) 1998-12-22 2004-04-21 Vollmers, Heinz Fragment des glycoproteins cd55/daf zur gewinnung hochwirksamer tumorarzneien sowie verfahren zu dessen verwendung
CA2796140A1 (en) 1999-03-25 2000-09-28 Jochen Salfeld Human antibodies that bind human il-12 and methods for producing
US7049132B1 (en) 1999-06-28 2006-05-23 University Of Southern California Stress-responsive induction of a therapeutic agent and methods of use
NZ517202A (en) * 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US6677442B1 (en) 1999-10-29 2004-01-13 University Of Kentucky Research Foundation Nucleic acid encoding human REV1 protein
DE60134459D1 (de) 2000-02-23 2008-07-31 Amgen Inc Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
DE60143798D1 (de) 2000-06-16 2011-02-17 Cambridge Antibody Tech Immunspezifisch bindende antikörper gegen blys
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
WO2002079377A2 (en) * 2000-11-08 2002-10-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
CA2443862A1 (en) * 2001-04-17 2002-10-24 Peizhi Luo Structure-based construction of human antibody library
EP1423425B1 (de) 2001-07-24 2010-12-01 Debiovision Inc. Rezeptor, dessen verwendung sowie mausantikörper
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
WO2004020999A1 (en) 2002-08-30 2004-03-11 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20040048243A1 (en) 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
ATE550352T1 (de) 2001-12-03 2012-04-15 Alexion Pharma Inc Verfahren zur herstellung von hybridantikörper
DE10210427A1 (de) * 2002-03-09 2003-10-09 Hans Konrad Mueller-Hermelink Humaner monoklonaler Antikörper
AU2003222069A1 (en) 2002-03-29 2003-10-20 Centocor, Inc. Mammalian cdr mimetibodies, compositions, methods and uses
EP1517921B1 (de) * 2002-06-28 2006-06-07 Domantis Limited Dual-specifische liganden mit erhöhter halbwertszeit
DE10230516A1 (de) 2002-07-06 2004-01-15 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
AU2003249533A1 (en) 2002-07-04 2004-01-23 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
SE0302312D0 (sv) 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
US20050123571A1 (en) 2003-06-06 2005-06-09 Rossini Aldo A. Modulation of apoptosis
US20050143291A1 (en) 2003-10-27 2005-06-30 Lee Amy S. Methods and compositions for modulating apoptosis
JP2007521020A (ja) 2003-11-12 2007-08-02 オンコマブ・ゲーエムベーハー 新生物特異的抗体を同定する方法及びその使用
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (de) 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
US20050191294A1 (en) 2003-12-31 2005-09-01 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy
GB0404936D0 (en) 2004-03-04 2004-04-07 Univ London Screen
DE102004015179A1 (de) 2004-03-25 2005-10-13 Oncomab Gmbh Antigen des PM-2 Antikörpers und dessen Verwendung
CA2683287A1 (en) 2006-11-27 2008-12-18 Patrys Limited Novel glycosylated peptide target in neoplastic cells
JP2012517216A (ja) 2009-02-09 2012-08-02 パトリス リミテッド Ｓａｍ−６変異体、標的および使用法

Also Published As

Publication number Publication date
EP1531162A1 (de) 2005-05-18
US20130039849A1 (en) 2013-02-14
WO2005047332A1 (en) 2005-05-26
EP1709083A1 (de) 2006-10-11
EP1709083B1 (de) 2012-04-18
US8741296B2 (en) 2014-06-03
JP2008507951A (ja) 2008-03-21
EP2341077A1 (de) 2011-07-06
AU2004289821B2 (en) 2011-10-06
AU2004289821A1 (en) 2005-05-26
US8163552B2 (en) 2012-04-24
US20080108133A1 (en) 2008-05-08
CA2545454A1 (en) 2005-05-26
CA2545454C (en) 2016-09-13

Similar Documents

Publication Publication Date Title
DK1706424T3 (da) FC-region varianter
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
CY1116913T1 (el) Τροποποιημενα κλασματα fab αντισωματων
DK1718677T3 (da) Monovalente antistoffragmenter egnede som terapeutiske midler
ATE541857T1 (de) Optimierte fc-varianten und herstellungsverfahren dafür
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
ATE461220T1 (de) Anti-egfr-antikörper
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
CY1112507T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για την ανθρωπινη ιl-1β
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
NO20091976L (no) Nye forbindelser
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
EP4105237A4 (de) Cldn18.2-antikörper und verwendung davon
EP1875237A4 (de) Docetaxel-immuntest
ATE377193T1 (de) Analyse von massenspektraldaten in den ruhigen gebieten
ATE357967T1 (de) Emulsionen mit oberflächenmodifizierten organischen molekülen
ATE554109T1 (de) Adenocarcinomspezifischer antikörper sam-6 und anwendungen dafür
EA200601220A1 (ru) Анти-trkc антитела-агонисты и способы их применения
ATE437185T1 (de) Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon
ATE411300T1 (de) Neue cysteine protease hemmers und ihre therapeutische anwendungen
DK1771732T3 (da) Taxol-immunassay
DE60335610D1 (de) Neoplasma-spezifische antikörper und deren verwendungen
ATE443135T1 (de) Fluoreszenzprotein und pigmentprotein
ATE483714T1 (de) Podophyllotoxine als antiproliferative mittel
NO20053903D0 (no) Nukleotidlipidesterderivater.